榴莲视频

Ian Ingram

Ian Ingram

Authors >

Ian Ingram

Ian Ingram joined 榴莲视频 in 2018 as Deputy Managing Editor, and covers oncology for the site. Ian Ingram has been a medical editor for the past decade. Prior to joining 榴莲视频, he was managing editor of Cancer Network, directing the website鈥檚 news coverage and video production. Ian has also worked as a fact-checker, was an assistant editor at Narrative Magazine, and a manuscript reader at the Paris Review. He holds a B.A. in journalism from Purchase College. Ian lives in Connecticut, enjoys tennis, and almost always bowls a perfect game.

Connect:

email image

Latest from Ian Ingram

Doctors performing colonic resection surgery.

Lidocaine Fails to Speed Up Gut Function Recovery After Colonic Surgery

Absence of gut function recovery is the primary reason for extended hospital stays

A photo of surgeons performing a liver transplant.

Alarming Surge in Alcohol-Related Liver Transplants in Younger Adults

Targeted preventive strategies needed, especially for younger women, researchers say

A photo of bottles of Ocaliva tablets over a computer rendering of the gallbladder with bile duct and biliary tree.

FDA Rejects Full Approval of Liver Disease Drug

Agency's decision on obeticholic acid in PBC follows negative advisory committee meeting

FDA APPROVED obecabtagene autoleucel (Aucatzyl) over a rendering of CAR-T cells attacking lymphoblastic leukemia cells.

New CAR T-Cell Therapy Approved for Leukemia

Obecabtagene autoleucel has no requirement for a REMS program

FDA APPROVED minocycline hydrochloride extended-release capsules (Emrosi) over a photo of a woman with rosacea on her cheeks

FDA Approves New Option for Rosacea

Antibiotic Emrosi topped doxycycline, placebo in phase III trials

FDA ADCOMM sotagliflozin over a computer rendering of chronic kidney disease.

FDA Staff Not Quite Sold on Sotagliflozin for T1D Patients With CKD

SGLT1/SGLT2 inhibitor has another shot in T1D, but now in more narrow patient population

A photo of the packaging and vial of Trodelvy.

Drugmaker Pulls Trodelvy's Bladder Cancer Approval

In confirmatory trial, antibody-drug conjugate failed to improve OS versus chemotherapy

FDA APPROVED dupilumab (Dupixent) over a computer rendering of a transparent body with the lung bronchi highlighted.

First-Ever Biologic Approved for COPD

Phase III trial program showed 30% to 34% reduction in moderate or severe exacerbations

FDA CRL tradipitant (Vanda) over a computer rendering of a stomach.

FDA Rejects NK1R Antagonist for Gastroparesis

Drugmaker none-too-pleased with agency's request for additional studies

FDA APPROVED benralizumab (Fasenra) over a photo of vasculitis rashes on a man鈥檚 leg and foot.

FDA OKs New Option for Rare Immune-Mediated Vasculitis

Benralizumab wins approval for eosinophilic granulomatosis with polyangiitis

1

鈥�